Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Follow-Up Questions
ONCO hissesinin fiyat performansı nasıl?
ONCO 'in mevcut fiyatı $3.06 'dir, son işlem günde 0% decreased etti.
Onconetix Inc için ana iş temaları veya sektörler nelerdir?
Onconetix Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Onconetix Inc 'in piyasa değerlemesi nedir?
Onconetix Inc 'in mevcut piyasa değerlemesi $4.7M 'dir
